Trove Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human SCGB1A1 protein (Therabron), which has potential clinical applications in a variety of respiratory diseases including persistent or chronic rhinosinusitis (CRS), acute lung injury (ALI) due to severe influenza, smoke inhalation, sepsis or shock, and bronchiolitis obliterans in lung and hematopoietic cell transplant recipients.